Baptist Heart & Vascular Institute Research
The research department is involved in a trial evaluating Apolipoprotein A-I in reducing major adverse cardiovascular events (MACE) in patients with acute coronary syndrome. Apolipoprotein A-I is a major component of HDL in plasma and promotes cholesterol efflux which is the first step in a process known as reverse cholesterol transport. It is thought that the rapid enhancement of the body’s ability to remove cholesterol from the arteries will reduce the rate of early recurrent CV events. The primary endpoint is the first occurrence of MACE from randomization to 90 days. Early studies showed no significant change in liver and kidney function and the Apolipoprotein A-I was well tolerated. Apolipoprotein A-I versus placebo is administered by IV infusion once a week for four weeks.
If you would like further information about our research program, please call 850-484-6690.